Although NKT-like cells are poorly known, previous studies have proposed that the CD3+CD56+NKT-like cells may be a crucial effector for the antitumor activities in surgery-treated colon carcinoma, radiotherapy-treated gastric cancer, and ICIs-treated hepatocellular carcinoma patients [41, 42]. This evidence concerns the gene NCAM1 and gastric cancer.